Esophagoprotection by rabeprazole mediated by restoration of an impairment in esophageal mucin production: Its potential therapeutic benefit in patients with gasteroesophageal reflux disease (GERD)
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2016
At a glance
- Drugs Rabeprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Pharmacodynamics
- 01 Aug 2007 Status changed from recruiting to completed.
- 06 Nov 2005 New trial record.